eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2006
vol. 10
 
Share:
Share:
abstract:

Targeted therapy of colorectal cancer – state of the art

Beata Utracka-Hutka

Współcz Onkol (2006) vol. 10; 3 (121-127)
Online publish date: 2006/04/12
View full text Get citation
 
The recent development of drugs that target the key components of biologic pathways rendered an improvement in survival in colorectal cancer patients. Two monoclonal antibodies in particular, targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) – bevacizumab and cetuximab are clinically available. The expectations with low molecular weight tyrosine kinase inhibitors in the treatment of colorectal cancer have not been confirmed. This review focuses on the defining role of the novel targeted agents in colorectal cancer.
keywords:

Colorectal cancer, targeted therapy, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF)

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.